Our Technology.

,

Proprietary Platform

A powerful and versatile technology platform includes proprietary antibody-conjugated nanoparticles that are specifically adapted to antigen peptides that are only present in the bloodstream when the targeted disease is active.

Versatile and Rapid

Diagnostic tests take a matter of hours instead of days and weeks in some cases such as AFB culture tests.  The platform can be adapted to different antigen targets and thus different diseases.  Ultimately, we were be able to provide a rapid response to unknown diseases and outbreaks.

Proven

The technology has been proven to work in thousands of patient samples for tuberculosis and HIV detection.  It is shown to detect extremely low concentrations in blood and the ability to detect when other methods can not.

Tuberculosis Still a Global Health Epidemic

TB remains a global epidemic with 10 million new cases and 1.5 million deaths annually.  Better diagnostics are required to support global health efforts to effectively combat this disease.  NanoPin's technology is uniquely qualified for active TB detection - we can detect both pulmonary and extrapulmonary TB in both adult patients and also much more difficult patient populations:  children, infants, HIV co-infected.  

HIV Millions Live with HIV

NanoPin's technology has the potential to shorten detection windows and find active disease sooner and significantly improve patient treatment.  HIV and TB are directly linked in that TB is the leading killer in HIV patients with 250,000 deaths annually (WHO, TB Annual Report).  NanoPin's assays can ultimately be used for both HIV detection and the detection of TB in HIV patients.

Pulmonary and ExtraPulmonary Detection

.